



iTrack™ Canaloplasty to be Featured at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans

California, USA, October 05, 2026 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary iTrack™ canaloplasty technology will be featured in one instructional course and three on-demand posters during the official scientific program of the 2026 American Academy of Ophthalmology (AAO) Annual Meeting, taking place at the Ernest N. Morial Convention Center in New Orleans, Louisiana, 9 – 12 October 2026.

This year's AAO Annual Meeting will spotlight the innovative iTrack™ and iTrack™ Advance canaloplasty technology through a comprehensive line-up: 1 instructional course and 3 on-demand posters from distinguished professionals in the field. These presentations will offer in-depth insights into long-term clinical outcomes, real-world performance and the evolving role of canaloplasty in the management of glaucoma – including 10-year follow-up data, multicentre real-world evidence and expert consensus recommendations.

A summary of the AAO 2026 presentations and posters featuring the iTrack™ and the iTrack™ Advance is included below:

Instructional Course

Saturday, 10 October 2026 | 9:45 – 11:00 AM CST | Room R05

Mary Qiu, MD (Senior Instructor); Shivani S. Kamat, MD; Daniel S. Petkovsek, MD; Rebecca Freedman Neustein, MD; Jessie Wang, MD

MIGS in Cataract Patients: Canaloplasty and Trabecular Meshwork Cutting Procedures
Session 220

On-Demand Posters

Justin Spaulding, DO; Austin P. Bell, MD; David M. Lubeck, MD; Richard G. Morshedi, MD; J. Morgan Micheletti, MD; Erin A. Doe, MD; Billy Xiaoyi Pan, MD; Zachary D. Vest, MD; Marshall J. Huang, MD; Audrey Mok, MD; Irene Fong Sasaki, MD; Julia Agapov, DO; Avneet K. Sodhi, MD; George Reiss, MD; Shamil S. Patel, MD

Real-World Multicenter Evaluation of Ab-Interno Canaloplasty Using iTrack Advance in Open-Angle Glaucoma



Larissa Camejo, MD; Craig Chaya, MD; Mark Gallardo, MD; Shivani Kamat, MD; Shamil Patel, MD; Rachel G. Simpson, MD; Robert Noecker, MD

Recommendations for Ab-Interno Canaloplasty in Glaucoma Management: Expert Consensus on Treatment Protocols and Outcomes

Mark J. Gallardo, MD; Brayden H. Koch, BS; Matthew S. Porter, MD

10-Year Effectiveness and Safety of Ab-Interno Canaloplasty Standalone or Combined With Phacoemulsification for the Treatment of Primary Open-Angle Glaucoma

Full session details can be accessed via the AAO 2026 Meeting Guide.

All educational content of the AAO Annual Meeting is planned by the Academy's Program Committees. The AAO does not endorse, promote, approve, or recommend the use of any products, devices, or services.

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

ABOUT CANALOPLASTY

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm's canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm's canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.



The iTrack™ Advance canaloplasty device has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma.

Indications for Use, US: The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures. The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.*

** The iTrack™ Advance cutting function (goniotomy) is a Class 1 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma.*

Indications for Use, International: The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.

For additional information about the iTrack™ Advance, including safety information, please visit:
<https://itrack-advance.com>

For media enquiries, please contact:

Kate Hunt: Nova Eye Chief Commercial Officer - khunt@nova-eye.com

Giorgio Pirazzini: GP Communications – giorgio@gpcommunications.eu